The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population

Journal of Cystic Fibrosis

Volumn 9, Issue 3, 2010, Pages 212-216

  Wagner, Brandie D ^a   Accurso, Frank J ^b   Laguna, Theresa A ^c  

^a Department of Civil and Environmental Engineering at Colorado State University and the Department of Environmental and Occupational Health at the Colorado School of Public Health   (United States)

^b Nutrition Obesity Research Center at the University of Colorado   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cystic fibrosis; Normalization factor; Pulmonary exacerbation; Specific gravity; Urinary biomarkers; Urinary creatinine

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; BIOLOGICAL MARKER; DESMOSINE; CREATININE;

ADOLESCENT; AGE DISTRIBUTION; AMINO ACID URINE LEVEL; ANALYTIC METHOD; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE URINE LEVEL; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PREDICTION; RELATIVE DENSITY; SEX DIFFERENCE; URINALYSIS; ASTHMA; CASE CONTROL STUDY; DISEASE COURSE; HOSPITAL PATIENT; REFERENCE VALUE; URINE; YOUNG ADULT;

ADOLESCENT; ASTHMA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CREATININE; CYSTIC FIBROSIS; DISEASE PROGRESSION; HUMANS; INPATIENTS; REFERENCE VALUES; SPECIFIC GRAVITY; YOUNG ADULT;

EID: 77953359191     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.02.004     Document Type: Article

References (30)

1. Martin M.D., Woods J.S., Leroux B.G., Rue T., Derouen T.A., Leitao J., et al. Longitudinal urinary creatinine excretion values among preadolescents and adolescents. Transl Res Jan 2008, 151(1):51-56.
2. Heavner D.L., Morgan W.T., Sears S.B., Richardson J.D., Byrd G.D., Ogden M.W. Effect of creatinine and specific gravity normalization techniques on xenobiotic biomarkers in smokers' spot and 24-h urines. J Pharm Biomed Anal Mar 3 2006, 40(4):928-942.
3. Suwazono Y., Akesson A., Alfven T., Jarup L., Vahter M. Creatinine versus specific gravity-adjusted urinary cadmium concentrations. Biomarkers Mar-Jun 2005, 10(2-3):117-126.
4. Alessio L., Berlin A., Dell'Orto A., Toffoletto F., Ghezzi I. Reliability of urinary creatinine as a parameter used to adjust values of urinary biological indicators. Int Arch Occup Environ Health 1985, 55(2):99-106.
5. Barr D.B., Wilder L.C., Caudill S.P., Gonzalez A.J., Needham L.L., Pirkle J.L. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect Feb 2005, 113(2):192-200.
6. Neubert A., Remer T. The impact of dietary protein intake on urinary creatinine excretion in a healthy pediatric population. J Pediatr Nov 1998, 133(5):655-659.
7. Penner S.B., Bernstein K.N., Fine A. Changes in endogenous creatinine clearance in man on a controlled protein diet: effect of route of administration of a protein load. Clin Invest Med Oct 1990, 13(5):233-236.
8. Worsfold M., Davie M.W., Haddaway M.J. Age-related changes in body composition, hydroxyproline, and creatinine excretion in normal women. Calcif Tissue Int Jan 1999, 64(1):40.
9. Jatlow P., McKee S., O'Malley S.S. Correction of urine cotinine concentrations for creatinine excretion: is it useful?. Clin Chem Nov 2003, 49(11):1932-1934.
10. Al-Aloul M., Jackson M., Bell G., Ledson M., Walshaw M. Comparison of methods of assessment of renal function in cystic fibrosis (CF) patients. J Cyst Fibros Jan 2007, 6(1):41-47.
11. Al-Aloul M., Miller H., Alapati S., Stockton P.A., Ledson M.J., Walshaw M.J. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol Jan 2005, 39(1):15-20.
12. Tan K.H., Mulheran M., Knox A.J., Smyth A.R. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med Mar 15 2003, 167(6):819-823.
13. Martinez-Salgado C., Lopez-Hernandez F.J., Lopez-Novoa J.M. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol Aug 15 2007, 223(1):86-98.
14. Rosenstein B.J., Cutting G.R. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr Apr 1998, 132(4):589-595.
15. Starcher B.C. Lung elastin and matrix. Chest 2000, 117:229S-234S.
16. Starcher B. A ninhydrin-based assay to quantitate the total protein content of tissue samples. Anal Biochem May 1 2001, 292(1):125-129.
17. Starcher B., Conrad M. A role for neutrophil elastase in the progression of solar elastosis. Connect Tissue Res 1995, 31(2):133-140.
18. King G.S., Mohan V.S., Starcher B.C. Radioimmunoassay for desmosine. Connect Tissue Res 1980, 7(4):263-267.
19. Starcher B., Green M., Scott M. Measurement of urinary desmosine as an indicator of acute pulmonary disease. Respiration 1995, 62(5):252-257.
20. Kronmal R.A. Spurious correlation and the fallacy of the ratio standard revisited. J R Stat Soc A 1993, 156:379-392.
21. Liu Y., Schutz R.W. Statistical validity of using ratio variables in human kinetics research. Res Q Exerc Sport Sep 2003, 74(3):226-235.
22. Tanner J.M. Fallacy of per-weight and per-surface area standards, and their relation to spurious correlation. J Appl Physiol Jul 1949, 2(1):1-15.
23. Allison D.B., Paultre F., Goran M.I., Poehlman E.T., Heymsfield S.B. Statistical considerations regarding the use of ratios to adjust data. Int J Obes Relat Metab Disord Sep 1995, 19(9):644-652.
24. Carrieri M., Trevisan A., Bartolucci G.B. Adjustment to concentration-dilution of spot urine samples: correlation between specific gravity and creatinine. Int Arch Occup Environ Health Jan 2001, 74(1):63-67.
25. Guman-Wignot T.M., Kaufman J., Holsclaw D.S., Schmoyer I.R., Alhadeff J.A. Analysis and HPLC fractionation of urine from patients with cystic fibrosis, chronic lung diseases and normal controls. Clin Biochem Oct 1989, 22(5):377-383.
26. Bode D.C., Pagani E.D., Cumiskey W.R., von Roemeling R., Hamel L., Silver P.J. Comparison of urinary desmosine excretion in patients with chronic obstructive pulmonary disease or cystic fibrosis. Pulm Pharmacol Ther 2000, 13(4):175-180.
27. Etherington C., Bosomworth M., Clifton I., Peckham D.G., Conway S.P. Measurement of urinary N-acetyl-b-d-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics. J Cyst Fibros Jan 2007, 6(1):67-73.
28. Halacova M., Kotaska K., Kukacka J., Vavrova V., Kuzelova M., Ticha J., et al. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin. J Clin Pharm Ther Aug 2008, 33(4):409-417.
29. Downey D.G., Martin S.L., Dempster M., Moore J.E., Keogan M.T., Starcher B., et al. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol Mar 2007, 42(3):216-220.
30. Stone P.J., Konstan M.W., Berger M., Dorkin H.L., Franzblau C., Snider G.L. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med Jul 1995, 152(1):157-162.